secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2023-08-10T23:59:59+00:00
Accession:  0000950170-23-041305
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kezar Life Sciences Q2 net loss $24.3M; cash $236.6M; clinical trials advancing
-------------------------------------------------------------------------------

- Net loss of $24.3M ($0.34 per share) vs $16.2M ($0.25) in Q2 2022.
- Cash equivalents and marketable securities $236.6M at June 30, 2023, down from $276.6M at Dec 31, 2022.
- R&D expenses rose to $21.0M from $11.3M year-over-year, driven by zetomipzomib and KZR-261 programs.
- PALIZADE Phase 2b (lupus nephritis) and PORTOLA Phase 2a (autoimmune hepatitis) open for enrollment; KZR-261 dose escalation continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023041305/0000950170-23-041305-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000095017023041305/kzr-20230810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-041305

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer